Sept 24 (Reuters) – Malaysia’s IHH Healthcare said on Thursday its subsidiary has appealed a Tokyo court’s dismissal of its damages claim against Daiichi Sankyo over the unit’s acquisition of a stake in India’s Fortis Healthcare.
On September 10, the court dismissed the claims of Northern TK Venture (NTK), and ruled that IHH’s unit shall bear the litigation costs. NTK had filed a petition in May 2025 seeking to revise damages from Daiichi Sankyo to up to 109.3 billion Indian rupees ($1.14 billion).
IHH said NTK suffered losses from delays in obtaining acquisition approvals due to a dispute between Daiichi Sankyo and “certain judgment debtors, to which IHH was not a party”, and has thus exercised its right of appeal.
Fortis, in an email to Reuters, pointed to IHH’s press release and did not comment separately. Daiichi Sankyo did not respond to Reuters requests for comment.
IHH, one of the world’s largest private healthcare groups, had bought a 31% interest in Fortis through NTK, but later halted its open offer to buy an additional 26% after the Japanese company filed a contempt plea against the founders of the Indian company.
The Malaysian firm also said on Thursday it plans to increase its stake in Fortis to 51% over the next three to five years, and further integrate its Fortis and Gleneagles platforms.
($1 = 95.9550 Indian rupees)
(Reporting by Shivangi Lahiri in Bengaluru; Editing by Vijay Kishore)
